
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Aetion, Inc announced the FDA and Brigham and Women's Hospital have expanded their demonstration project. The first use of RWE to predict treatment safety and efficacy, and time researchers will estimate the results of randomized controlled trials that have not yet concluded.
Read more






